Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor-induced immune dysfunction.

R Kiessling1, K Wasserman, S Horiguchi

  • 1Cancer Center Karolinska, Immune- and Genetherapy Laboratory, KS-ringen R8:01, Karolinska Hospital, S-171 76 Stockholm, Sweden. Rolf.Kiessling@mtc.ki.se

Cancer Immunology, Immunotherapy : CII
|September 29, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a limiter-like Langmuir probe system for the Q-shu university experiment with steady-state spherical tokamak (QUEST) all-metal device.

The Review of scientific instruments·2025
Same author

Measurement of electron temperature anisotropy in ohmically heated plasmas in TST-2 using a double-pass Thomson scattering system.

The Review of scientific instruments·2025
Same author

Maximum flexion and lateral rollback revealed better patient satisfaction after total knee arthroplasty.

Knee surgery & related research·2024
Same author

Stress urinary incontinence after hysterectomy: a 10-year national follow-up study.

Archives of gynecology and obstetrics·2022
Same author

Surgical results of Hybrid Mita method to idiopathic scoliosis: minimum two years follow-up.

Studies in health technology and informatics·2021
Same author

Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer.

Scientific reports·2021
Same journal

NKG2A-HLA-E and TIM3-galectin 9 pathways promote immune inhibition and represent therapeutic vulnerabilities in pancreatic ductal adenocarcinoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

Integrative analysis of small cell carcinoma of the uterine cervix reveals its heterogeneity and provides novel predictive markers.

Cancer immunology, immunotherapy : CII·2026
Same journal

EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses.

Cancer immunology, immunotherapy : CII·2026
Same journal

Multidimensional analysis of tumour immune microenvironment in HCC: prognostic significance and implications for immunotherapy.

Cancer immunology, immunotherapy : CII·2026
Same journal

Transcriptomic landscape of peripheral T cells following CAR-T cell therapy in diffuse large B cell lymphoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

HMGB1 ubiquitination inhibition and extracellular secretion, mediated by m<sup>6</sup>A modified-exosomal lncRNA MALAT1, creates a communication between NK92-MI cells and tumor cells to aggravate acute lymphoblastic leukemia.

Cancer immunology, immunotherapy : CII·2026
See all related articles

Immune therapies using cytotoxic T lymphocytes (CTL) and natural killer (NK) cells show promise in mice but face challenges in human cancer treatment due to immune suppression. New insights may lead to improved cancer and infectious disease immunotherapies.

Area of Science:

  • Immunology
  • Oncology
  • Infectious Diseases

Background:

  • Immune-based cancer therapies have historically focused on cytotoxic T lymphocytes (CTL) and natural killer (NK) cells.
  • While successful in preclinical models, CTL and NK cell-based approaches have limited clinical efficacy in cancer patients.
  • Tumor-associated immune suppression hinders the effectiveness of these cellular immunotherapies.

Purpose of the Study:

  • To discuss the causes of immune suppression affecting CTL and NK cell activity in cancer.
  • To explore parallels between tumor-associated immune suppression and conditions like HIV infection, leprosy, and rheumatoid arthritis.
  • To highlight recent findings that suggest novel immunotherapeutic strategies for cancer and infectious diseases.

Main Methods:

Related Experiment Videos

  • Review of existing literature on immune suppression in cancer.
  • Comparative analysis of immune dysfunction in malignancy and other diseases (HIV, leprosy, rheumatoid arthritis).
  • Discussion of recent research on cellular immune alterations and their therapeutic implications.

    • Main Results:

    • Significant differences exist between immune responses in tumor-bearing mice and human cancer patients.
    • Tumor-associated immune suppression shares mechanisms with immune dysregulation observed in HIV infection, leprosy, and rheumatoid arthritis.
    • Recent discoveries illuminate the causes of dysfunctional CTL and NK cells in disease.

    Conclusions:

    • Understanding immune suppression is critical for advancing cancer immunotherapy.
    • Shared mechanisms of immune dysfunction offer potential cross-therapeutic insights.
    • Emerging research provides a basis for developing next-generation immunotherapies for cancer and infectious diseases.